# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 7.2 | 69.5 | (22.4-162.2) |  | Male | 7 | 4.7 | 149.5 | (59.9-308.0) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 7 | 3.2 | 220.8 | (88.4-454.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 32 | 27.3 | 117.2 | (80.1-165.4) |  | Female | 5 | 3.1 | 159.9 | (51.5-373.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 7.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 6.5 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 23.9 | 100.4 | (64.3-149.5) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 2.8 | 215.6 | (78.7-469.2) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 10 | 6.1 | 163.9 | (78.5-301.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 13.3 | 45.3 | (16.5-98.5) |  | Male | 69 | 94.6 | 72.9 | (56.7-92.3) |
| Female | 1 | 11.9 | nc | (nc-nc) |  | Female | 82 | 87.0 | 94.2 | (74.9-116.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

61

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 14.9 | 147.5 | (92.4-223.4) |  | Male | 11 | 9.3 | 118.2 | (58.9-211.5) |
| Female | 9 | 5.4 | 165.7 | (75.6-314.6) |  | Female | 11 | 7.3 | 150.0 | (74.8-268.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 6 | 3.0 | 199.4 | (72.8-434.0) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 8.2 | nc | (nc-nc) |
| Female | 48 | 61.8 | 77.7 | (57.3-103.0) |  | Female | 7 | 7.5 | 93.8 | (37.6-193.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.8 | 103.5 | (41.5-213.3) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 15.2 | 105.4 | (60.2-171.2) |  |  |  |  |  |  |
| Female | 15 | 15.2 | 98.5 | (55.1-162.4) |  | Female | 1 | 5.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.7 | 162.5 | (59.4-353.8) |  | Male | 7 | 5.5 | 128.3 | (51.4-264.3) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 5.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 28 | 44.0 | 63.6 | (42.3-92.0) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 8.3 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 6 | 4.9 | 122.6 | (44.8-266.9) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 5 | 3.5 | 143.9 | (46.4-335.8) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 6 | 10.5 | 57.3 | (20.9-124.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 18 | 14.4 | 125.2 | (74.2-197.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 26.2 | 126.2 | (86.8-177.2) |  | Male | 170 | 185.1 | 91.8 | (78.5-106.7) |
| Female | 44 | 28.9 | 152.0 | (110.5-204.1) |  | Female | 192 | 203.8 | 94.2 | (81.4-108.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

62

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 9 | 6.3 | 142.4 | (65.0-270.3) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 5.3 | 94.7 | (30.5-221.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 26 | 22.0 | 118.1 | (77.1-173.1) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 26 | 21.4 | 121.5 | (79.4-178.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

63

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 13.4 | 142.3 | (85.6-222.2) |  | Male | 6 | 8.9 | 67.5 | (24.6-146.9) |
| Female | 5 | 4.5 | 111.7 | (36.0-260.6) |  | Female | 4 | 7.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 9 | 7.9 | 114.1 | (52.1-216.6) |
| Female | 50 | 57.9 | 86.3 | (64.1-113.8) |  | Female | 7 | 6.6 | 106.0 | (42.5-218.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 6.9 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 14.9 | 46.9 | (18.8-96.6) |  |  |  |  |  |  |
| Female | 16 | 13.7 | 116.9 | (66.8-189.8) |  | Female | 5 | 4.9 | 101.6 | (32.7-237.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 9 | 5.1 | 177.1 | (80.8-336.3) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 33 | 42.0 | 78.7 | (54.1-110.5) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 8.3 | 144.8 | (74.7-253.0) |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 3 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 5.6 | 125.6 | (50.3-258.9) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 17 | 11.5 | 147.4 | (85.8-236.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 9 | 13.3 | 67.9 | (31.0-128.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 23.1 | 90.9 | (56.3-139.0) |  | Male | 153 | 176.5 | 86.7 | (73.5-101.6) |
| Female | 22 | 23.3 | 94.6 | (59.2-143.2) |  | Female | 177 | 185.5 | 95.4 | (81.9-110.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

64

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 15.3 | 71.9 | (35.8-128.7) |  | Male | 25 | 8.7 | 288.1 | (186.4-425.4) |
| Female | 11 | 4.8 | 228.7 | (114.0-409.2) |  | Female | 15 | 5.2 | 288.5 | (161.4-475.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 11 | 7.6 | 144.5 | (72.0-258.6) |
| Female | 40 | 43.5 | 92.0 | (65.8-125.3) |  | Female | 6 | 5.9 | 101.4 | (37.0-220.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 5.7 | 140.8 | (60.6-277.5) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 14.0 | 128.4 | (76.0-202.9) |  |  |  |  |  |  |
| Female | 11 | 12.5 | 88.3 | (44.0-158.0) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 6 | 5.3 | 113.4 | (41.4-246.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 5 | 5.0 | 99.9 | (32.2-233.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 39 | 39.8 | 98.0 | (69.7-134.0) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.2 | 83.7 | (30.6-182.1) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 5.3 | 170.1 | (77.6-322.9) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 2 | 5.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 9 | 10.3 | 87.7 | (40.0-166.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 26.4 | 64.5 | (37.5-103.2) |  | Male | 175 | 172.0 | 101.7 | (87.2-118.0) |
| Female | 26 | 25.4 | 102.5 | (66.9-150.2) |  | Female | 164 | 154.8 | 105.9 | (90.4-123.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

65

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 40.8 | 127.4 | (95.1-167.0) |  | Male | 21 | 26.4 | 79.6 | (49.3-121.7) |
| Female | 15 | 15.8 | 94.7 | (52.9-156.2) |  | Female | 22 | 21.3 | 103.4 | (64.8-156.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 7.6 | 158.2 | (81.6-276.4) |  | Male | 7 | 8.4 | 83.2 | (33.3-171.5) |
| Female | 5 | 6.8 | 73.3 | (23.6-171.1) |  | Female | 9 | 7.4 | 122.4 | (55.8-232.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 27 | 23.2 | 116.5 | (76.8-169.5) |
| Female | 179 | 174.6 | 102.5 | (88.1-118.7) |  | Female | 10 | 21.5 | 46.5 | (22.3-85.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 19.5 | 112.9 | (70.8-171.0) |
| Female | 5 | 5.5 | 90.6 | (29.2-211.5) |  | Female | 7 | 9.4 | 74.1 | (29.7-152.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 42.9 | 91.0 | (64.7-124.4) |  |  |  |  |  |  |
| Female | 51 | 44.1 | 115.5 | (86.0-151.9) |  | Female | 23 | 14.9 | 154.5 | (97.9-231.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 10.3 | 87.3 | (39.9-165.8) |  | Male | 19 | 15.2 | 125.4 | (75.4-195.8) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 24 | 16.4 | 146.7 | (94.0-218.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 129 | 121.7 | 106.0 | (88.5-125.9) |
| Female | 3 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 23.6 | 93.0 | (58.3-140.9) |  | Male | 5 | 9.6 | 52.0 | (16.8-121.4) |
| Female | 13 | 14.1 | 92.3 | (49.1-157.9) |  | Female | 3 | 6.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  | Male | 7 | 5.4 | 130.4 | (52.2-268.7) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 16.3 | 98.1 | (56.1-159.4) |  | Male | 11 | 10.5 | 104.3 | (52.0-186.7) |
| Female | 23 | 12.4 | 186.0 | (117.9-279.1) |  | Female | 33 | 30.5 | 108.1 | (74.4-151.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 14.5 | 103.6 | (57.9-170.8) |  |  |  |  |  |  |
| Female | 2 | 5.2 | nc | (nc-nc) |  | Female | 47 | 39.8 | 118.2 | (86.8-157.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 60 | 71.9 | 83.4 | (63.7-107.4) |  | Male | 531 | 519.3 | 102.2 | (93.7-111.3) |
| Female | 71 | 84.8 | 83.7 | (65.4-105.6) |  | Female | 608 | 584.3 | 104.1 | (96.0-112.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

66

# Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 24.4 | 73.7 | (43.6-116.4) |  | Male | 8 | 17.2 | 46.4 | (20.0-91.4) |
| Female | 9 | 8.8 | 101.7 | (46.4-193.1) |  | Female | 11 | 14.7 | 74.9 | (37.3-134.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 6.2 | 96.4 | (35.2-209.8) |  | Male | 8 | 5.2 | 153.1 | (65.9-301.6) |
| Female | 6 | 5.1 | 117.0 | (42.7-254.7) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 14 | 15.7 | 89.4 | (48.8-149.9) |
| Female | 99 | 109.3 | 90.5 | (73.6-110.2) |  | Female | 19 | 13.0 | 146.0 | (87.9-228.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 12.8 | 54.5 | (21.8-112.3) |
| Female | 9 | 4.3 | 209.9 | (95.8-398.4) |  | Female | 9 | 5.8 | 155.5 | (71.0-295.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 28.3 | 116.6 | (80.2-163.7) |  |  |  |  |  |  |
| Female | 12 | 26.6 | 45.1 | (23.3-78.8) |  | Female | 5 | 9.4 | 53.1 | (17.1-123.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 6.2 | nc | (nc-nc) |  | Male | 9 | 9.2 | 97.5 | (44.5-185.0) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 16 | 9.3 | 172.4 | (98.5-280.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 52 | 71.5 | 72.7 | (54.3-95.3) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 15.8 | 44.3 | (17.7-91.2) |  | Male | 8 | 6.0 | 133.6 | (57.5-263.3) |
| Female | 12 | 8.6 | 139.3 | (71.9-243.3) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 4 | 7.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 11.7 | 85.6 | (41.0-157.5) |  | Male | 13 | 8.9 | 145.5 | (77.4-248.9) |
| Female | 12 | 8.4 | 142.0 | (73.3-248.1) |  | Female | 43 | 25.9 | 166.3 | (120.3-224.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 8.8 | 136.1 | (70.2-237.7) |  |  |  |  |  |  |
| Female | 12 | 3.0 | 396.7 | (204.7-692.9) |  | Female | 16 | 23.6 | 67.8 | (38.7-110.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 53 | 41.6 | 127.5 | (95.5-166.8) |  | Male | 301 | 332.2 | 90.6 | (80.7-101.4) |
| Female | 65 | 46.5 | 139.8 | (107.9-178.1) |  | Female | 396 | 364.7 | 108.6 | (98.2-119.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

67

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.2 | 96.0 | (30.9-224.0) |  | Male | 6 | 3.2 | 189.7 | (69.3-412.9) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 18 | 17.3 | 104.0 | (61.6-164.3) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.1 | 117.8 | (43.0-256.3) |  |  |  |  |  |  |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 13 | 15.7 | 83.0 | (44.1-141.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.1 | 122.7 | (39.5-286.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 9.2 | 130.0 | (67.1-227.1) |  | Male | 55 | 63.7 | 86.3 | (65.0-112.3) |
| Female | 6 | 8.5 | 71.0 | (25.9-154.5) |  | Female | 49 | 57.3 | 85.5 | (63.3-113.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

68

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 5 | 5.5 | 91.6 | (29.5-213.7) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 1.7 | 289.7 | (93.3-675.9) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 5.3 | 94.3 | (30.4-220.2) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 20 | 21.2 | 94.2 | (57.5-145.6) |
| Female | 4 | 1.9 | nc | (nc-nc) |  | Female | 15 | 16.7 | 89.7 | (50.2-147.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

69

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 6.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 4.8 | 125.9 | (46.0-273.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 3 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 22 | 18.0 | 122.2 | (76.6-185.1) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 11 | 19.3 | 57.1 | (28.5-102.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

70

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 57 | 65.0 | 87.6 | (66.4-113.5) |  | Male | 21 | 40.9 | 51.3 | (31.7-78.4) |
| Female | 21 | 24.1 | 87.0 | (53.8-133.0) |  | Female | 20 | 31.9 | 62.7 | (38.3-96.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 12.1 | 58.0 | (23.2-119.5) |  | Male | 11 | 13.2 | 83.3 | (41.6-149.1) |
| Female | 11 | 10.4 | 106.0 | (52.8-189.6) |  | Female | 6 | 11.1 | 54.1 | (19.8-117.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 30 | 36.3 | 82.7 | (55.8-118.1) |
| Female | 260 | 254.6 | 102.1 | (90.1-115.3) |  | Female | 39 | 32.4 | 120.4 | (85.6-164.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 30 | 29.6 | 101.4 | (68.4-144.8) |
| Female | 11 | 7.9 | 139.7 | (69.6-249.9) |  | Female | 22 | 14.2 | 155.0 | (97.1-234.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 95 | 66.5 | 142.8 | (115.5-174.5) |  |  |  |  |  |  |
| Female | 60 | 67.7 | 88.7 | (67.7-114.1) |  | Female | 28 | 22.3 | 125.6 | (83.4-181.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 16.1 | 99.1 | (56.6-161.0) |  | Male | 19 | 23.8 | 80.0 | (48.1-124.9) |
| Female | 6 | 4.7 | 128.5 | (46.9-279.7) |  | Female | 24 | 25.2 | 95.3 | (61.0-141.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 121 | 189.5 | 63.8 | (53.0-76.3) |
| Female | 1 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 43 | 36.2 | 118.8 | (85.9-160.0) |  | Male | 11 | 15.1 | 73.1 | (36.4-130.7) |
| Female | 28 | 20.7 | 135.0 | (89.7-195.2) |  | Female | 9 | 9.5 | 94.4 | (43.1-179.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 9.4 | 117.6 | (58.6-210.4) |  | Male | 10 | 8.6 | 116.0 | (55.5-213.3) |
| Female | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 25.9 | 88.9 | (56.3-133.4) |  | Male | 13 | 15.8 | 82.1 | (43.7-140.5) |
| Female | 10 | 19.0 | 52.7 | (25.2-96.9) |  | Female | 34 | 44.8 | 75.9 | (52.5-106.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 22.1 | 58.7 | (31.2-100.4) |  |  |  |  |  |  |
| Female | 7 | 7.9 | 88.5 | (35.5-182.4) |  | Female | 54 | 58.5 | 92.3 | (69.3-120.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 135 | 113.3 | 119.2 | (99.9-141.1) |  | Male | 722 | 811.6 | 89.0 | (82.6-95.7) |
| Female | 136 | 125.6 | 108.3 | (90.8-128.1) |  | Female | 866 | 870.7 | 99.5 | (92.9-106.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

71

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 2 | 6.2 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 4.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 14 | 19.6 | 71.6 | (39.1-120.1) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 11 | 19.8 | 55.5 | (27.7-99.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

72

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 5 | 8.8 | 57.0 | (18.4-132.9) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 7.6 | 105.5 | (45.4-207.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 4.9 | 101.3 | (32.6-236.3) |  | Male | 28 | 33.4 | 83.9 | (55.8-121.3) |
| Female | 5 | 4.3 | 115.5 | (37.2-269.5) |  | Female | 23 | 29.2 | 78.9 | (50.0-118.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

73

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 12.4 | 217.5 | (143.3-316.5) |  | Male | 10 | 8.3 | 120.5 | (57.7-221.6) |
| Female | 5 | 5.1 | 98.4 | (31.7-229.6) |  | Female | 12 | 7.3 | 165.5 | (85.4-289.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 7.4 | 67.6 | (21.8-157.9) |
| Female | 56 | 57.4 | 97.6 | (73.7-126.7) |  | Female | 9 | 7.0 | 127.7 | (58.3-242.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.2 | 80.0 | (25.8-186.7) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 5 | 3.1 | 159.5 | (51.4-372.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 13.5 | 148.1 | (90.5-228.8) |  |  |  |  |  |  |
| Female | 12 | 14.7 | 81.6 | (42.1-142.6) |  | Female | 7 | 5.0 | 140.8 | (56.4-290.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 56 | 39.0 | 143.7 | (108.6-186.7) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 7.6 | 170.2 | (90.5-291.0) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 6 | 4.6 | 131.0 | (47.9-285.2) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 5.3 | 151.0 | (65.0-297.5) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 7 | 4.2 | 165.8 | (66.4-341.6) |  | Female | 14 | 11.1 | 126.5 | (69.1-212.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 4.5 | 242.5 | (120.9-433.9) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 16 | 13.0 | 123.0 | (70.2-199.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 21.8 | 133.1 | (89.1-191.2) |  | Male | 216 | 164.7 | 131.1 | (114.2-149.9) |
| Female | 31 | 26.3 | 117.9 | (80.1-167.3) |  | Female | 216 | 192.7 | 112.1 | (97.7-128.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

74

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 9.0 | 100.1 | (45.7-190.0) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 6 | 3.4 | 179.0 | (65.4-389.5) |  | Female | 15 | 4.8 | 314.7 | (176.0-519.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.2 | 114.4 | (41.8-249.1) |
| Female | 44 | 39.4 | 111.6 | (81.1-149.8) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.4 | 137.3 | (50.1-298.8) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 9.5 | 105.5 | (50.5-194.0) |  |  |  |  |  |  |
| Female | 4 | 9.5 | nc | (nc-nc) |  | Female | 5 | 3.3 | 151.6 | (48.8-353.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 28 | 26.4 | 105.9 | (70.3-153.0) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.3 | 113.5 | (41.5-247.1) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 5 | 2.7 | 183.6 | (59.2-428.5) |  | Female | 10 | 7.3 | 136.6 | (65.4-251.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 7 | 8.5 | 82.1 | (32.9-169.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 16.0 | 68.9 | (34.3-123.2) |  | Male | 105 | 115.5 | 90.9 | (74.4-110.1) |
| Female | 12 | 18.1 | 66.4 | (34.3-116.0) |  | Female | 132 | 128.7 | 102.6 | (85.8-121.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

75

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 13 | 8.5 | 153.6 | (81.7-262.7) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 7.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 19 | 31.8 | 59.8 | (36.0-93.4) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 34 | 27.5 | 123.8 | (85.7-173.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

76

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 27.4 | 117.0 | (80.0-165.1) |  | Male | 27 | 17.4 | 155.5 | (102.4-226.2) |
| Female | 11 | 9.7 | 113.8 | (56.7-203.6) |  | Female | 30 | 12.2 | 246.4 | (166.2-351.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.9 | 103.0 | (33.2-240.3) |  | Male | 5 | 5.6 | 88.5 | (28.5-206.6) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 15 | 15.3 | 98.0 | (54.8-161.6) |
| Female | 130 | 99.3 | 130.9 | (109.3-155.4) |  | Female | 10 | 12.8 | 78.1 | (37.4-143.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 12.9 | 85.6 | (42.7-153.1) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 8 | 5.6 | 143.8 | (61.9-283.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 28.6 | 59.5 | (34.6-95.2) |  |  |  |  |  |  |
| Female | 30 | 27.2 | 110.1 | (74.3-157.2) |  | Female | 16 | 8.6 | 185.4 | (105.9-301.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 6.9 | nc | (nc-nc) |  | Male | 8 | 10.1 | 79.3 | (34.2-156.3) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 8 | 10.2 | 78.7 | (33.9-155.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 82 | 81.0 | 101.2 | (80.5-125.6) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 15.7 | 38.3 | (14.0-83.4) |  | Male | 4 | 6.4 | nc | (nc-nc) |
| Female | 11 | 8.1 | 136.3 | (67.9-243.9) |  | Female | 0 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.0 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 10.6 | 94.0 | (45.0-172.8) |  | Male | 6 | 6.8 | 88.4 | (32.3-192.4) |
| Female | 3 | 7.3 | nc | (nc-nc) |  | Female | 17 | 15.9 | 106.8 | (62.2-171.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.5 | 74.0 | (29.6-152.4) |  |  |  |  |  |  |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 26 | 22.8 | 114.2 | (74.6-167.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 47.7 | 37.8 | (22.4-59.7) |  | Male | 285 | 343.6 | 82.9 | (73.6-93.2) |
| Female | 29 | 49.2 | 59.0 | (39.5-84.7) |  | Female | 377 | 339.5 | 111.0 | (100.1-122.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

77

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 7 | 10.3 | 68.0 | (27.2-140.0) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 8.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 27 | 33.1 | 81.5 | (53.7-118.6) |
| Female | 1 | 4.3 | nc | (nc-nc) |  | Female | 18 | 32.1 | 56.2 | (33.3-88.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

78

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 9 | 5.1 | 177.0 | (80.8-336.1) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 1.4 | 367.6 | (118.5-857.8) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 15 | 15.4 | 97.3 | (54.4-160.6) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 21 | 17.2 | 122.1 | (75.5-186.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

79

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 10.2 | 78.1 | (33.6-154.0) |  | Male | 6 | 6.2 | 97.4 | (35.6-211.9) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 3 | 5.4 | nc | (nc-nc) |
| Female | 24 | 36.2 | 66.2 | (42.4-98.5) |  | Female | 2 | 4.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 10.2 | 68.8 | (27.6-141.7) |  |  |  |  |  |  |
| Female | 8 | 9.9 | 80.8 | (34.8-159.2) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 22 | 26.1 | 84.4 | (52.9-127.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 5.2 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 0 | 5.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 7 | 8.2 | 85.6 | (34.3-176.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 17.3 | 104.2 | (61.7-164.7) |  | Male | 91 | 119.1 | 76.4 | (61.5-93.8) |
| Female | 15 | 18.3 | 82.2 | (46.0-135.5) |  | Female | 90 | 123.8 | 72.7 | (58.5-89.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

80

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 37.2 | 88.6 | (61.0-124.5) |  | Male | 15 | 22.8 | 65.9 | (36.8-108.7) |
| Female | 18 | 13.7 | 131.8 | (78.1-208.3) |  | Female | 15 | 17.3 | 86.7 | (48.5-143.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 6.2 | 192.3 | (99.3-336.0) |  | Male | 2 | 7.3 | nc | (nc-nc) |
| Female | 5 | 5.5 | 90.5 | (29.2-211.3) |  | Female | 3 | 6.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 16 | 20.1 | 79.6 | (45.5-129.3) |
| Female | 150 | 136.9 | 109.6 | (92.7-128.6) |  | Female | 21 | 17.9 | 117.4 | (72.6-179.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 15.8 | 126.9 | (77.5-195.9) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 9 | 7.7 | 116.5 | (53.2-221.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 37.3 | 91.2 | (63.1-127.4) |  |  |  |  |  |  |
| Female | 36 | 38.7 | 93.0 | (65.2-128.8) |  | Female | 13 | 11.9 | 108.9 | (57.9-186.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 8.8 | 113.4 | (54.3-208.5) |  | Male | 15 | 13.3 | 112.8 | (63.1-186.0) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 12 | 14.4 | 83.2 | (42.9-145.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 97 | 100.1 | 96.9 | (78.6-118.3) |
| Female | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 19.5 | 102.6 | (62.7-158.5) |  | Male | 6 | 8.4 | 71.1 | (25.9-154.7) |
| Female | 16 | 11.2 | 142.4 | (81.3-231.2) |  | Female | 6 | 5.5 | 109.6 | (40.0-238.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 7 | 4.0 | 173.9 | (69.7-358.3) |
| Female | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 14.2 | 63.3 | (28.9-120.2) |  | Male | 9 | 8.3 | 108.6 | (49.5-206.1) |
| Female | 13 | 10.7 | 121.7 | (64.7-208.1) |  | Female | 31 | 23.1 | 134.0 | (91.1-190.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 11.9 | 58.6 | (23.5-120.8) |  |  |  |  |  |  |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 41 | 30.4 | 134.9 | (96.8-183.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 63 | 63.3 | 99.5 | (76.4-127.3) |  | Male | 424 | 444.2 | 95.5 | (86.6-105.0) |
| Female | 65 | 68.8 | 94.5 | (72.9-120.4) |  | Female | 505 | 475.2 | 106.3 | (97.2-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

81

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 42.2 | 125.6 | (94.0-164.2) |  | Male | 23 | 25.8 | 89.2 | (56.5-133.9) |
| Female | 17 | 15.5 | 110.0 | (64.0-176.1) |  | Female | 11 | 19.5 | 56.5 | (28.2-101.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 7.4 | 94.5 | (37.8-194.6) |  | Male | 5 | 8.3 | 60.4 | (19.5-140.9) |
| Female | 6 | 6.5 | 92.7 | (33.8-201.7) |  | Female | 7 | 7.0 | 99.9 | (40.0-205.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 22 | 22.9 | 96.1 | (60.2-145.5) |
| Female | 134 | 155.4 | 86.2 | (72.3-102.1) |  | Female | 17 | 20.3 | 83.9 | (48.8-134.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 18.1 | 99.2 | (58.8-156.8) |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 6 | 8.9 | 67.7 | (24.7-147.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 42.3 | 89.8 | (63.5-123.2) |  |  |  |  |  |  |
| Female | 48 | 43.6 | 110.1 | (81.2-146.0) |  | Female | 9 | 13.6 | 66.1 | (30.2-125.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 10.1 | 128.8 | (68.5-220.3) |  | Male | 15 | 15.1 | 99.4 | (55.6-164.0) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 7 | 16.4 | 42.6 | (17.0-87.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 127 | 117.2 | 108.3 | (90.3-128.9) |
| Female | 2 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 22.3 | 94.1 | (58.2-143.9) |  | Male | 13 | 9.6 | 135.7 | (72.2-232.0) |
| Female | 15 | 12.7 | 117.9 | (65.9-194.5) |  | Female | 12 | 6.1 | 195.5 | (100.9-341.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 5.8 | 138.3 | (59.5-272.5) |  | Male | 4 | 4.8 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 16.4 | 91.5 | (51.2-150.9) |  | Male | 10 | 9.4 | 106.2 | (50.8-195.3) |
| Female | 9 | 12.0 | 74.8 | (34.1-142.0) |  | Female | 36 | 25.9 | 138.8 | (97.2-192.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 13.6 | 102.7 | (56.1-172.4) |  |  |  |  |  |  |
| Female | 1 | 4.9 | nc | (nc-nc) |  | Female | 27 | 35.3 | 76.5 | (50.4-111.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 72 | 72.4 | 99.4 | (77.8-125.2) |  | Male | 511 | 510.0 | 100.2 | (91.7-109.3) |
| Female | 50 | 78.3 | 63.9 | (47.4-84.2) |  | Female | 450 | 539.7 | 83.4 | (75.9-91.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

82

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 31.2 | 102.7 | (70.2-145.0) |  | Male | 25 | 18.9 | 132.1 | (85.5-195.0) |
| Female | 15 | 12.9 | 116.3 | (65.0-191.8) |  | Female | 21 | 15.8 | 132.5 | (82.0-202.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.4 | 148.3 | (63.9-292.3) |  | Male | 7 | 6.1 | 115.6 | (46.3-238.2) |
| Female | 6 | 5.1 | 117.6 | (43.0-256.0) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 24 | 16.9 | 142.3 | (91.2-211.8) |
| Female | 152 | 123.0 | 123.6 | (104.7-144.9) |  | Female | 18 | 16.6 | 108.1 | (64.1-170.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 12.9 | 147.1 | (88.5-229.8) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 11 | 7.1 | 155.2 | (77.4-277.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 31.2 | 93.0 | (62.3-133.5) |  |  |  |  |  |  |
| Female | 35 | 36.5 | 95.9 | (66.8-133.4) |  | Female | 6 | 11.0 | 54.7 | (20.0-119.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.3 | nc | (nc-nc) |  | Male | 17 | 11.0 | 153.9 | (89.6-246.4) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 17 | 13.6 | 125.0 | (72.8-200.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 89 | 82.8 | 107.5 | (86.4-132.3) |
| Female | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 25 | 16.1 | 155.3 | (100.4-229.2) |  | Male | 8 | 7.0 | 113.7 | (49.0-224.1) |
| Female | 14 | 10.3 | 135.5 | (74.0-227.3) |  | Female | 7 | 5.1 | 136.8 | (54.8-282.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 4.2 | 119.8 | (38.6-279.5) |  | Male | 6 | 3.9 | 154.9 | (56.6-337.2) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 12.1 | 99.5 | (51.4-173.8) |  | Male | 6 | 7.0 | 86.0 | (31.4-187.2) |
| Female | 8 | 10.1 | 79.5 | (34.2-156.6) |  | Female | 25 | 20.6 | 121.1 | (78.3-178.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 9.8 | 112.4 | (56.0-201.1) |  |  |  |  |  |  |
| Female | 5 | 4.1 | 122.7 | (39.5-286.3) |  | Female | 27 | 27.1 | 99.7 | (65.7-145.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 52.4 | 93.5 | (69.2-123.6) |  | Male | 419 | 370.3 | 113.2 | (102.6-124.5) |
| Female | 81 | 64.2 | 126.1 | (100.2-156.8) |  | Female | 494 | 436.5 | 113.2 | (103.4-123.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

83

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 6 | 3.3 | 179.7 | (65.6-391.1) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 5 | 3.2 | 156.6 | (50.5-365.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 19 | 26.4 | 72.0 | (43.3-112.4) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 5.4 | 148.3 | (63.8-292.2) |  |  |  |  |  |  |
| Female | 7 | 6.5 | 108.0 | (43.3-222.6) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 16 | 17.0 | 94.1 | (53.7-152.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 9 | 6.2 | 145.4 | (66.3-276.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 8.6 | nc | (nc-nc) |  | Male | 60 | 66.8 | 89.8 | (68.5-115.6) |
| Female | 9 | 12.1 | 74.2 | (33.8-140.8) |  | Female | 71 | 86.8 | 81.8 | (63.9-103.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

84

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 51 | 32.0 | 159.6 | (118.8-209.9) |  | Male | 37 | 18.0 | 205.5 | (144.7-283.3) |
| Female | 16 | 11.6 | 138.4 | (79.1-224.8) |  | Female | 27 | 12.7 | 213.3 | (140.5-310.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  | Male | 11 | 6.0 | 183.2 | (91.3-327.9) |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 5 | 5.1 | 97.5 | (31.4-227.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 13 | 15.7 | 82.7 | (44.0-141.4) |
| Female | 116 | 107.3 | 108.1 | (89.3-129.7) |  | Female | 12 | 14.4 | 83.1 | (42.9-145.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 11.6 | 120.6 | (65.9-202.3) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 3 | 6.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 28.7 | 80.0 | (50.7-120.1) |  |  |  |  |  |  |
| Female | 25 | 29.5 | 84.8 | (54.8-125.1) |  | Female | 19 | 9.4 | 203.1 | (122.2-317.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 7.3 | 164.4 | (84.9-287.3) |  | Male | 9 | 11.0 | 81.8 | (37.3-155.3) |
| Female | 6 | 2.2 | 267.4 | (97.7-582.1) |  | Female | 12 | 11.9 | 100.7 | (52.0-175.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 100 | 83.5 | 119.7 | (97.4-145.6) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 14.8 | 40.5 | (14.8-88.1) |  | Male | 2 | 6.9 | nc | (nc-nc) |
| Female | 7 | 9.2 | 76.4 | (30.6-157.4) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 11.1 | 90.2 | (43.2-165.9) |  | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 7 | 8.0 | 87.4 | (35.0-180.2) |  | Female | 13 | 13.8 | 94.1 | (50.1-160.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 9.3 | 85.9 | (37.0-169.2) |  |  |  |  |  |  |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 22 | 25.8 | 85.1 | (53.3-128.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 48 | 55.9 | 85.9 | (63.4-113.9) |  | Male | 391 | 358.5 | 109.1 | (98.5-120.4) |
| Female | 63 | 61.9 | 101.8 | (78.2-130.2) |  | Female | 394 | 377.3 | 104.4 | (94.4-115.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

85

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 7.9 | 126.3 | (60.5-232.4) |  | Male | 8 | 5.3 | 149.8 | (64.5-295.2) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.7 | 106.8 | (34.4-249.3) |
| Female | 26 | 31.4 | 82.8 | (54.1-121.4) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 8.8 | 124.4 | (62.0-222.7) |  |  |  |  |  |  |
| Female | 8 | 8.2 | 97.3 | (41.9-191.7) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 21 | 24.4 | 86.1 | (53.3-131.6) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.9 | 101.3 | (32.6-236.3) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 9 | 7.1 | 127.2 | (58.0-241.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 14.1 | 70.9 | (33.9-130.3) |  | Male | 110 | 104.6 | 105.1 | (86.4-126.7) |
| Female | 15 | 15.2 | 98.9 | (55.3-163.2) |  | Female | 91 | 106.3 | 85.6 | (68.9-105.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

86

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 8.2 | 134.8 | (67.2-241.2) |  | Male | 12 | 5.7 | 211.0 | (108.9-368.6) |
| Female | 6 | 2.3 | 263.7 | (96.3-574.0) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 5 | 1.9 | 268.8 | (86.6-627.2) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.0 | 99.1 | (31.9-231.3) |
| Female | 33 | 35.3 | 93.6 | (64.4-131.4) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.5 | 132.7 | (48.5-288.9) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 9.1 | 87.4 | (37.7-172.3) |  |  |  |  |  |  |
| Female | 9 | 7.0 | 128.6 | (58.7-244.1) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 25 | 27.5 | 90.9 | (58.8-134.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.4 | 111.4 | (40.7-242.4) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 5 | 2.5 | 196.1 | (63.2-457.6) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 8 | 7.5 | 107.3 | (46.2-211.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 6 | 7.9 | 75.5 | (27.6-164.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 15.0 | 106.4 | (60.8-172.7) |  | Male | 123 | 113.1 | 108.7 | (90.4-129.7) |
| Female | 13 | 13.2 | 98.4 | (52.3-168.2) |  | Female | 104 | 106.5 | 97.7 | (79.8-118.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

87

# Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 8.0 | nc | (nc-nc) |  | Male | 10 | 4.9 | 202.3 | (96.9-372.1) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.3 | 161.2 | (64.6-332.2) |
| Female | 31 | 27.7 | 111.8 | (76.0-158.7) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 8.2 | 85.7 | (34.3-176.5) |  |  |  |  |  |  |
| Female | 2 | 6.2 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 22 | 22.2 | 99.1 | (62.1-150.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.3 | 115.2 | (37.1-268.9) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 6 | 5.2 | 116.0 | (42.3-252.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 6.2 | 81.3 | (26.2-189.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 13.9 | 57.7 | (24.8-113.6) |  | Male | 88 | 96.9 | 90.8 | (72.8-111.9) |
| Female | 6 | 11.4 | 52.8 | (19.3-114.9) |  | Female | 72 | 86.4 | 83.4 | (65.2-105.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

88

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 30.5 | 114.9 | (80.0-159.8) |  | Male | 15 | 20.3 | 73.8 | (41.3-121.7) |
| Female | 17 | 10.6 | 160.5 | (93.4-256.9) |  | Female | 17 | 16.0 | 106.4 | (61.9-170.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 6.3 | 142.3 | (64.9-270.1) |  | Male | 9 | 6.5 | 138.6 | (63.3-263.2) |
| Female | 3 | 5.2 | nc | (nc-nc) |  | Female | 4 | 5.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 12 | 17.9 | 67.1 | (34.6-117.2) |
| Female | 137 | 129.2 | 106.1 | (89.0-125.4) |  | Female | 12 | 15.1 | 79.2 | (40.9-138.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 15.7 | 101.6 | (58.1-165.1) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 10 | 6.9 | 146.0 | (69.9-268.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 36 | 32.6 | 110.4 | (77.3-152.9) |  |  |  |  |  |  |
| Female | 44 | 30.6 | 143.7 | (104.4-192.9) |  | Female | 11 | 11.1 | 99.2 | (49.4-177.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.1 | 160.4 | (85.3-274.3) |  | Male | 9 | 11.6 | 77.8 | (35.5-147.8) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 12 | 10.9 | 110.2 | (56.9-192.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 82 | 99.2 | 82.7 | (65.8-102.6) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 18.9 | 105.9 | (64.6-163.5) |  | Male | 11 | 7.3 | 150.2 | (74.9-268.7) |
| Female | 16 | 10.2 | 157.4 | (89.9-255.6) |  | Female | 5 | 4.3 | 116.2 | (37.4-271.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 4.7 | 168.9 | (72.7-332.8) |  | Male | 5 | 4.9 | 101.8 | (32.8-237.5) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 12.8 | 124.9 | (71.3-202.8) |  | Male | 8 | 8.7 | 92.3 | (39.8-181.9) |
| Female | 5 | 8.9 | 56.4 | (18.2-131.7) |  | Female | 24 | 25.4 | 94.5 | (60.5-140.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 11.6 | 103.6 | (53.4-180.9) |  |  |  |  |  |  |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 27 | 29.7 | 90.8 | (59.8-132.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 81 | 55.1 | 147.1 | (116.8-182.8) |  | Male | 445 | 407.5 | 109.2 | (99.3-119.8) |
| Female | 75 | 57.3 | 130.9 | (103.0-164.1) |  | Female | 472 | 422.1 | 111.8 | (102.0-122.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

89

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 11.4 | 105.0 | (54.2-183.4) |  | Male | 5 | 7.6 | 65.7 | (21.2-153.4) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 7 | 5.2 | 133.4 | (53.4-274.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 6.8 | 73.6 | (23.7-171.7) |
| Female | 46 | 42.8 | 107.6 | (78.8-143.5) |  | Female | 5 | 4.8 | 103.9 | (33.5-242.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 12.2 | 90.4 | (45.1-161.8) |  |  |  |  |  |  |
| Female | 11 | 9.9 | 111.2 | (55.4-199.0) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 3 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 34 | 35.1 | 96.8 | (67.0-135.3) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 6.9 | 232.1 | (132.6-377.0) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 7 | 3.3 | 214.8 | (86.0-442.5) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 4.8 | 186.8 | (85.2-354.6) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 6 | 2.9 | 206.9 | (75.6-450.4) |  | Female | 11 | 8.8 | 124.5 | (62.1-222.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 16 | 9.7 | 165.5 | (94.6-268.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 20.5 | 97.4 | (59.5-150.5) |  | Male | 155 | 150.2 | 103.2 | (87.6-120.8) |
| Female | 26 | 17.4 | 149.3 | (97.5-218.8) |  | Female | 172 | 137.1 | 125.4 | (107.4-145.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

90

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 14 | 16.7 | 83.8 | (45.8-140.6) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.9 | 129.5 | (41.7-302.3) |  |  |  |  |  |  |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 11.4 | 87.6 | (41.9-161.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 3 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.7 | 136.0 | (43.8-317.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 6.2 | nc | (nc-nc) |  | Male | 42 | 46.7 | 89.9 | (64.8-121.5) |
| Female | 8 | 6.5 | 122.8 | (52.9-242.0) |  | Female | 45 | 51.9 | 86.8 | (63.3-116.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

91

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 19.3 | 134.5 | (87.8-197.0) |  | Male | 31 | 12.3 | 251.8 | (171.0-357.4) |
| Female | 2 | 6.4 | nc | (nc-nc) |  | Female | 12 | 9.2 | 131.0 | (67.6-228.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.5 | 141.2 | (45.5-329.6) |  | Male | 9 | 4.1 | 221.5 | (101.1-420.5) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 18 | 10.9 | 164.9 | (97.7-260.6) |
| Female | 85 | 77.2 | 110.1 | (88.0-136.2) |  | Female | 6 | 8.9 | 67.2 | (24.5-146.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 9.6 | 52.3 | (16.9-122.0) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 20.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 12 | 19.0 | 63.0 | (32.5-110.1) |  | Female | 9 | 6.5 | 138.5 | (63.2-263.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  | Male | 4 | 7.3 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 8 | 6.8 | 118.1 | (50.8-232.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 74 | 62.9 | 117.6 | (92.3-147.6) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 11.5 | 138.7 | (79.2-225.2) |  | Male | 2 | 4.6 | nc | (nc-nc) |
| Female | 3 | 5.9 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.6 | 104.7 | (45.1-206.4) |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 7 | 5.2 | 134.8 | (54.0-277.7) |  | Female | 8 | 13.6 | 58.7 | (25.3-115.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 7.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 11 | 17.5 | 63.0 | (31.4-112.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 34.3 | 78.7 | (51.9-114.6) |  | Male | 252 | 251.0 | 100.4 | (88.4-113.6) |
| Female | 22 | 33.4 | 65.8 | (41.2-99.7) |  | Female | 216 | 249.5 | 86.6 | (75.4-98.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

92

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 14.1 | 113.8 | (65.0-184.8) |  | Male | 12 | 9.3 | 129.0 | (66.6-225.3) |
| Female | 2 | 6.3 | nc | (nc-nc) |  | Female | 10 | 8.6 | 116.5 | (55.8-214.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.2 | 109.1 | (49.8-207.2) |
| Female | 53 | 71.1 | 74.5 | (55.8-97.5) |  | Female | 11 | 8.5 | 128.8 | (64.2-230.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 7.0 | 128.8 | (58.8-244.5) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 15.1 | 125.9 | (75.8-196.6) |  |  |  |  |  |  |
| Female | 10 | 17.6 | 56.9 | (27.2-104.6) |  | Female | 7 | 6.1 | 115.2 | (46.2-237.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.6 | 165.2 | (60.3-359.6) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.5 | 108.4 | (43.4-223.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 51 | 43.6 | 117.0 | (87.1-153.8) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 8.6 | 175.3 | (98.1-289.2) |  | Male | 0 | 3.4 | nc | (nc-nc) |
| Female | 5 | 5.7 | 87.6 | (28.2-204.5) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 4 | 5.0 | nc | (nc-nc) |  | Female | 11 | 12.7 | 86.9 | (43.3-155.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 10 | 16.2 | 61.9 | (29.6-113.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 25.1 | 95.5 | (61.2-142.1) |  | Male | 199 | 184.0 | 108.2 | (93.7-124.3) |
| Female | 22 | 34.0 | 64.7 | (40.5-98.0) |  | Female | 179 | 235.8 | 75.9 | (65.2-87.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

93

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 6 | 9.8 | 61.3 | (22.4-133.4) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 9.4 | 106.4 | (50.9-195.6) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 5 | 2.3 | 214.8 | (69.2-501.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 5.6 | 89.3 | (28.8-208.4) |  | Male | 40 | 39.7 | 100.8 | (72.0-137.3) |
| Female | 7 | 4.2 | 166.7 | (66.8-343.5) |  | Female | 29 | 31.3 | 92.7 | (62.1-133.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

94

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 23.0 | 60.9 | (33.3-102.2) |  | Male | 13 | 13.7 | 94.9 | (50.5-162.3) |
| Female | 5 | 8.6 | 58.1 | (18.7-135.6) |  | Female | 11 | 10.9 | 101.2 | (50.5-181.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 14 | 12.1 | 115.3 | (63.0-193.5) |
| Female | 80 | 86.0 | 93.0 | (73.8-115.8) |  | Female | 11 | 11.3 | 97.0 | (48.3-173.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 9.7 | 103.6 | (49.6-190.6) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 22.9 | 108.9 | (70.5-160.8) |  |  |  |  |  |  |
| Female | 33 | 24.2 | 136.4 | (93.8-191.5) |  | Female | 11 | 7.5 | 145.9 | (72.8-261.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 7 | 8.2 | 85.9 | (34.4-176.9) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 7 | 9.0 | 77.4 | (31.0-159.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 52 | 62.8 | 82.8 | (61.9-108.6) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 11.8 | 118.7 | (64.9-199.2) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 5 | 7.1 | 70.8 | (22.8-165.2) |  | Female | 6 | 3.4 | 174.4 | (63.7-379.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 8.7 | nc | (nc-nc) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 3 | 6.7 | nc | (nc-nc) |  | Female | 12 | 14.3 | 83.7 | (43.2-146.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 7.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 22 | 19.3 | 113.8 | (71.3-172.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 38.3 | 96.7 | (68.1-133.2) |  | Male | 231 | 271.7 | 85.0 | (74.4-96.7) |
| Female | 45 | 43.4 | 103.7 | (75.6-138.7) |  | Female | 288 | 298.6 | 96.5 | (85.6-108.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

95

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 10.9 | 128.7 | (70.3-216.0) |  | Male | 13 | 6.1 | 211.5 | (112.5-361.7) |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 6 | 4.0 | 148.8 | (54.3-323.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.5 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.3 | 93.5 | (30.1-218.2) |
| Female | 50 | 34.2 | 146.2 | (108.5-192.7) |  | Female | 6 | 4.5 | 133.7 | (48.8-291.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 4.2 | 168.3 | (67.4-346.8) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 10.0 | 140.5 | (76.7-235.7) |  |  |  |  |  |  |
| Female | 9 | 9.2 | 97.8 | (44.6-185.7) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 7 | 3.6 | 192.8 | (77.2-397.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 32 | 29.7 | 107.6 | (73.6-151.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.2 | 97.0 | (31.3-226.4) |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 3.8 | 185.0 | (74.1-381.3) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 2 | 4.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 3 | 8.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 18.7 | 149.5 | (99.3-216.1) |  | Male | 156 | 123.9 | 125.9 | (106.9-147.3) |
| Female | 14 | 19.0 | 73.7 | (40.3-123.7) |  | Female | 127 | 118.8 | 106.9 | (89.1-127.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

96

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 19.4 | 61.7 | (31.8-107.8) |  | Male | 10 | 12.6 | 79.6 | (38.1-146.4) |
| Female | 5 | 6.8 | 73.6 | (23.7-171.7) |  | Female | 4 | 9.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 15 | 11.1 | 135.6 | (75.8-223.6) |
| Female | 75 | 76.2 | 98.4 | (77.4-123.4) |  | Female | 7 | 9.4 | 74.4 | (29.8-153.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 9.3 | 107.1 | (51.3-196.9) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 20.3 | 127.9 | (83.6-187.5) |  |  |  |  |  |  |
| Female | 18 | 19.3 | 93.1 | (55.1-147.1) |  | Female | 1 | 6.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 7 | 7.3 | 96.5 | (38.7-198.8) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 11 | 7.0 | 156.2 | (77.9-279.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 45 | 59.5 | 75.6 | (55.2-101.2) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 11.3 | 123.8 | (67.6-207.8) |  | Male | 6 | 4.6 | 130.9 | (47.8-284.8) |
| Female | 6 | 6.1 | 98.4 | (35.9-214.1) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 7.6 | 65.4 | (21.1-152.6) |  | Male | 1 | 5.0 | nc | (nc-nc) |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 8 | 14.0 | 57.1 | (24.6-112.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 2.3 | 215.5 | (69.5-503.0) |  | Female | 23 | 17.7 | 130.0 | (82.4-195.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 34.7 | 74.9 | (48.9-109.8) |  | Male | 207 | 249.3 | 83.0 | (72.1-95.1) |
| Female | 43 | 35.7 | 120.5 | (87.2-162.3) |  | Female | 244 | 255.3 | 95.6 | (83.9-108.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

97

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 21.9 | 128.1 | (85.1-185.1) |  | Male | 23 | 14.6 | 157.8 | (100.0-236.8) |
| Female | 12 | 7.9 | 151.3 | (78.1-264.3) |  | Female | 10 | 11.9 | 84.1 | (40.3-154.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.6 | 130.4 | (47.6-283.8) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 7 | 3.8 | 184.1 | (73.8-379.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 10 | 13.0 | 77.1 | (36.9-141.9) |
| Female | 113 | 98.7 | 114.5 | (94.3-137.6) |  | Female | 12 | 11.4 | 105.3 | (54.3-183.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 11.4 | 87.8 | (42.0-161.5) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 5 | 5.1 | 97.2 | (31.3-226.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 23.7 | 59.1 | (32.3-99.2) |  |  |  |  |  |  |
| Female | 26 | 22.9 | 113.5 | (74.1-166.4) |  | Female | 11 | 8.3 | 132.9 | (66.3-237.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 12 | 8.3 | 144.2 | (74.4-251.9) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 12 | 8.2 | 147.1 | (75.9-256.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 94 | 71.8 | 130.8 | (105.7-160.1) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 13.8 | 123.4 | (71.8-197.5) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 5 | 7.6 | 65.4 | (21.1-152.5) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 9.2 | 173.0 | (98.8-280.9) |  | Male | 6 | 6.2 | 96.6 | (35.3-210.2) |
| Female | 3 | 6.6 | nc | (nc-nc) |  | Female | 20 | 19.1 | 104.7 | (64.0-161.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 8.3 | 120.6 | (57.7-221.8) |  |  |  |  |  |  |
| Female | 5 | 2.7 | 182.3 | (58.8-425.4) |  | Female | 21 | 22.3 | 94.0 | (58.2-143.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 39.7 | 85.6 | (59.3-119.7) |  | Male | 324 | 293.9 | 110.2 | (98.6-122.9) |
| Female | 50 | 43.1 | 115.9 | (86.0-152.8) |  | Female | 354 | 318.7 | 111.1 | (99.8-123.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

98

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 6.8 | 87.9 | (32.1-191.3) |  | Male | 18 | 4.3 | 415.6 | (246.2-656.8) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 3.8 | 130.8 | (42.1-305.2) |
| Female | 29 | 19.9 | 146.0 | (97.8-209.8) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 3.4 | 178.4 | (65.1-388.3) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 7.1 | 140.1 | (67.1-257.7) |  |  |  |  |  |  |
| Female | 4 | 5.1 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 21.7 | 110.7 | (70.9-164.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 6 | 3.2 | 185.5 | (67.8-403.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 4.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 11.7 | 110.6 | (58.9-189.2) |  | Male | 101 | 87.5 | 115.4 | (94.0-140.2) |
| Female | 9 | 9.6 | 93.5 | (42.7-177.6) |  | Female | 72 | 66.4 | 108.5 | (84.9-136.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

99

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 6 | 7.4 | 81.5 | (29.8-177.4) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 2.6 | 194.2 | (62.6-453.3) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 7.7 | 77.9 | (28.5-169.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 4.6 | nc | (nc-nc) |  | Male | 22 | 31.7 | 69.5 | (43.5-105.2) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 25 | 25.8 | 96.9 | (62.7-143.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

100

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 4 | 8.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 6.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 3.6 | 140.3 | (45.2-327.3) |  | Male | 18 | 26.7 | 67.3 | (39.9-106.4) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 21 | 28.7 | 73.2 | (45.3-111.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

101

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  | Male | 7 | 3.2 | 220.2 | (88.2-453.8) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 3 | 0.7 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 18 | 17.5 | 102.8 | (60.9-162.5) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 4 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 16.2 | 55.6 | (25.4-105.6) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 8.9 | 112.3 | (53.7-206.5) |  | Male | 58 | 64.8 | 89.5 | (68.0-115.7) |
| Female | 9 | 8.0 | 112.8 | (51.5-214.2) |  | Female | 59 | 56.5 | 104.5 | (79.5-134.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

102

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 37.4 | 85.6 | (58.5-120.8) |  | Male | 22 | 25.0 | 88.1 | (55.2-133.5) |
| Female | 12 | 13.6 | 88.0 | (45.4-153.7) |  | Female | 9 | 20.9 | 43.0 | (19.6-81.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 8.0 | nc | (nc-nc) |  | Male | 9 | 7.8 | 114.7 | (52.3-217.7) |
| Female | 4 | 7.0 | nc | (nc-nc) |  | Female | 2 | 6.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 22 | 22.2 | 99.0 | (62.0-150.0) |
| Female | 146 | 161.2 | 90.6 | (76.5-106.5) |  | Female | 17 | 19.5 | 87.2 | (50.8-139.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 18.4 | 98.0 | (58.1-154.9) |
| Female | 13 | 5.9 | 219.1 | (116.5-374.7) |  | Female | 11 | 8.6 | 127.7 | (63.7-228.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 40.0 | 99.9 | (71.4-136.0) |  |  |  |  |  |  |
| Female | 27 | 40.4 | 66.8 | (44.0-97.2) |  | Female | 12 | 13.9 | 86.4 | (44.6-150.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 9.5 | 115.4 | (57.5-206.6) |  | Male | 15 | 13.9 | 107.8 | (60.3-177.8) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 13 | 14.2 | 91.3 | (48.6-156.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 88 | 111.1 | 79.2 | (63.5-97.6) |
| Female | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 22.5 | 115.3 | (75.3-169.0) |  | Male | 16 | 8.9 | 179.6 | (102.6-291.6) |
| Female | 15 | 12.7 | 118.0 | (66.0-194.6) |  | Female | 7 | 5.7 | 123.5 | (49.5-254.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 5.6 | 143.8 | (61.9-283.4) |  | Male | 7 | 7.1 | 98.6 | (39.5-203.1) |
| Female | 5 | 1.7 | 294.3 | (94.8-686.7) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 16.1 | 105.7 | (61.5-169.3) |  | Male | 13 | 11.0 | 118.0 | (62.8-201.8) |
| Female | 11 | 11.8 | 92.9 | (46.3-166.2) |  | Female | 29 | 34.3 | 84.7 | (56.7-121.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 22 | 13.4 | 164.3 | (102.9-248.7) |  |  |  |  |  |  |
| Female | 6 | 4.6 | 130.1 | (47.5-283.1) |  | Female | 27 | 35.6 | 75.9 | (50.0-110.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 69 | 66.3 | 104.0 | (80.9-131.6) |  | Male | 470 | 488.5 | 96.2 | (87.7-105.3) |
| Female | 73 | 71.0 | 102.8 | (80.6-129.3) |  | Female | 478 | 537.3 | 89.0 | (81.2-97.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

103

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 22.5 | 106.8 | (68.4-158.9) |  | Male | 8 | 13.8 | 58.0 | (25.0-114.2) |
| Female | 20 | 8.6 | 232.5 | (142.0-359.1) |  | Female | 5 | 10.7 | 46.5 | (15.0-108.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 7 | 4.4 | 157.5 | (63.1-324.5) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 11 | 12.1 | 90.6 | (45.2-162.2) |
| Female | 80 | 85.7 | 93.4 | (74.1-116.2) |  | Female | 15 | 11.2 | 134.4 | (75.1-221.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 9.9 | 50.3 | (16.2-117.4) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 22.7 | 74.8 | (43.6-119.8) |  |  |  |  |  |  |
| Female | 22 | 24.0 | 91.8 | (57.5-139.0) |  | Female | 14 | 7.6 | 184.5 | (100.8-309.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 5.5 | nc | (nc-nc) |  | Male | 6 | 8.1 | 73.9 | (27.0-160.8) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 7 | 9.0 | 77.6 | (31.1-159.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 62 | 64.9 | 95.5 | (73.2-122.4) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 12.1 | 140.2 | (81.6-224.5) |  | Male | 3 | 5.1 | nc | (nc-nc) |
| Female | 7 | 7.1 | 98.4 | (39.4-202.8) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 3.1 | 159.3 | (51.3-371.7) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 8.5 | 70.2 | (25.6-152.8) |  | Male | 3 | 5.1 | nc | (nc-nc) |
| Female | 10 | 6.5 | 153.1 | (73.3-281.7) |  | Female | 14 | 14.0 | 99.7 | (54.5-167.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 7.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 18 | 19.7 | 91.4 | (54.2-144.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 38.6 | 101.1 | (71.9-138.2) |  | Male | 245 | 274.5 | 89.3 | (78.4-101.2) |
| Female | 36 | 44.2 | 81.5 | (57.1-112.8) |  | Female | 286 | 297.9 | 96.0 | (85.2-107.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

104

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 101 | 87.6 | 115.3 | (93.9-140.1) |  | Male | 26 | 56.4 | 46.1 | (30.1-67.6) |
| Female | 37 | 38.3 | 96.7 | (68.0-133.2) |  | Female | 24 | 51.4 | 46.7 | (29.9-69.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 17 | 17.2 | 99.1 | (57.7-158.7) |  | Male | 12 | 17.9 | 66.9 | (34.5-116.9) |
| Female | 14 | 16.7 | 83.6 | (45.7-140.3) |  | Female | 13 | 17.5 | 74.1 | (39.4-126.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 48 | 50.1 | 95.8 | (70.6-127.0) |
| Female | 317 | 403.6 | 78.5 | (70.1-87.7) |  | Female | 38 | 51.5 | 73.7 | (52.2-101.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 38 | 41.6 | 91.4 | (64.7-125.5) |
| Female | 19 | 13.0 | 145.7 | (87.7-227.5) |  | Female | 22 | 22.4 | 98.0 | (61.4-148.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 108 | 92.0 | 117.4 | (96.3-141.7) |  |  |  |  |  |  |
| Female | 115 | 109.0 | 105.6 | (87.1-126.7) |  | Female | 18 | 35.3 | 51.0 | (30.2-80.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 18 | 22.0 | 81.9 | (48.5-129.4) |  | Male | 35 | 32.4 | 108.1 | (75.3-150.3) |
| Female | 4 | 7.4 | nc | (nc-nc) |  | Female | 42 | 40.1 | 104.7 | (75.4-141.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 10 | 7.0 | 143.8 | (68.8-264.5) |  | Male | 278 | 262.7 | 105.8 | (93.8-119.0) |
| Female | 7 | 6.7 | 104.2 | (41.8-214.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 56 | 50.8 | 110.2 | (83.3-143.1) |  | Male | 34 | 20.6 | 165.4 | (114.5-231.1) |
| Female | 35 | 32.9 | 106.5 | (74.2-148.1) |  | Female | 28 | 15.3 | 182.5 | (121.2-263.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 12.8 | 132.7 | (77.3-212.6) |  | Male | 12 | 13.4 | 89.9 | (46.4-157.0) |
| Female | 8 | 4.6 | 175.2 | (75.4-345.2) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 35 | 35.9 | 97.4 | (67.9-135.5) |  | Male | 16 | 23.1 | 69.2 | (39.5-112.4) |
| Female | 34 | 30.7 | 110.7 | (76.6-154.6) |  | Female | 91 | 73.9 | 123.2 | (99.2-151.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 36 | 30.5 | 117.9 | (82.5-163.2) |  |  |  |  |  |  |
| Female | 10 | 12.4 | 80.8 | (38.7-148.6) |  | Female | 93 | 90.4 | 102.9 | (83.0-126.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 258 | 153.3 | 168.3 | (148.4-190.2) |  | Male | 1256 | 1119.3 | 112.2 | (106.1-118.6) |
| Female | 200 | 197.5 | 101.3 | (87.7-116.3) |  | Female | 1277 | 1384.9 | 92.2 | (87.2-97.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

105

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 47 | 57.2 | 82.1 | (60.3-109.2) |  | Male | 36 | 33.5 | 107.4 | (75.2-148.7) |
| Female | 13 | 20.9 | 62.1 | (33.0-106.2) |  | Female | 33 | 24.2 | 136.5 | (93.9-191.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 8.6 | 162.2 | (88.6-272.2) |  | Male | 8 | 11.0 | 73.0 | (31.4-143.9) |
| Female | 10 | 7.6 | 131.2 | (62.8-241.3) |  | Female | 10 | 9.3 | 107.1 | (51.3-197.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 32 | 29.3 | 109.1 | (74.6-154.1) |
| Female | 204 | 199.8 | 102.1 | (88.6-117.1) |  | Female | 13 | 26.5 | 49.1 | (26.1-84.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 28 | 23.0 | 121.8 | (80.9-176.1) |
| Female | 2 | 5.3 | nc | (nc-nc) |  | Female | 11 | 11.5 | 96.0 | (47.9-171.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 52 | 54.6 | 95.2 | (71.1-124.8) |  |  |  |  |  |  |
| Female | 52 | 55.8 | 93.2 | (69.6-122.2) |  | Female | 22 | 17.5 | 125.5 | (78.6-190.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 13.4 | 89.5 | (46.2-156.4) |  | Male | 14 | 20.2 | 69.3 | (37.9-116.4) |
| Female | 5 | 4.0 | 124.6 | (40.1-290.7) |  | Female | 14 | 21.8 | 64.2 | (35.1-107.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 183 | 157.1 | 116.5 | (100.2-134.6) |
| Female | 2 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 28.6 | 101.5 | (68.0-145.8) |  | Male | 10 | 12.7 | 78.7 | (37.7-144.7) |
| Female | 15 | 16.9 | 88.9 | (49.7-146.7) |  | Female | 3 | 7.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 13 | 7.7 | 168.3 | (89.5-287.8) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 29 | 20.7 | 140.4 | (94.0-201.6) |  | Male | 8 | 10.5 | 76.5 | (32.9-150.7) |
| Female | 6 | 15.1 | 39.6 | (14.5-86.3) |  | Female | 15 | 28.8 | 52.1 | (29.1-85.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 17.7 | 96.1 | (56.0-153.9) |  |  |  |  |  |  |
| Female | 3 | 6.5 | nc | (nc-nc) |  | Female | 33 | 46.5 | 70.9 | (48.8-99.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 74 | 99.3 | 74.5 | (58.5-93.5) |  | Male | 665 | 667.4 | 99.6 | (92.2-107.5) |
| Female | 118 | 110.2 | 107.1 | (88.6-128.2) |  | Female | 644 | 699.6 | 92.1 | (85.1-99.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

106

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 39.9 | 130.4 | (97.4-171.0) |  | Male | 17 | 25.8 | 66.0 | (38.4-105.6) |
| Female | 20 | 13.8 | 145.1 | (88.6-224.1) |  | Female | 15 | 19.2 | 78.2 | (43.7-129.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 8.0 | nc | (nc-nc) |  | Male | 4 | 8.2 | nc | (nc-nc) |
| Female | 13 | 6.6 | 198.4 | (105.5-339.2) |  | Female | 6 | 6.3 | 94.8 | (34.6-206.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 13 | 22.9 | 56.8 | (30.2-97.2) |
| Female | 147 | 151.5 | 97.0 | (82.0-114.1) |  | Female | 15 | 18.7 | 80.1 | (44.8-132.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 18.7 | 117.5 | (73.6-178.0) |
| Female | 8 | 5.0 | 160.1 | (68.9-315.5) |  | Female | 8 | 8.3 | 96.5 | (41.6-190.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 41.8 | 95.6 | (68.3-130.2) |  |  |  |  |  |  |
| Female | 45 | 39.5 | 114.0 | (83.1-152.5) |  | Female | 12 | 13.2 | 90.7 | (46.8-158.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 9.9 | 60.4 | (22.0-131.4) |  | Male | 17 | 14.7 | 115.9 | (67.5-185.6) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 9 | 14.3 | 62.8 | (28.6-119.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 84 | 115.1 | 73.0 | (58.2-90.3) |
| Female | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 22.9 | 117.9 | (77.7-171.6) |  | Male | 12 | 9.3 | 128.4 | (66.2-224.2) |
| Female | 16 | 12.3 | 129.8 | (74.2-210.9) |  | Female | 6 | 5.5 | 108.6 | (39.7-236.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.8 | nc | (nc-nc) |  | Male | 6 | 6.2 | 96.0 | (35.1-209.0) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 16.6 | 84.4 | (46.1-141.5) |  | Male | 8 | 10.5 | 75.9 | (32.7-149.5) |
| Female | 17 | 11.6 | 147.0 | (85.6-235.4) |  | Female | 32 | 29.1 | 110.1 | (75.3-155.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 13.8 | 115.9 | (66.2-188.3) |  |  |  |  |  |  |
| Female | 6 | 4.5 | 133.5 | (48.7-290.5) |  | Female | 29 | 33.5 | 86.5 | (57.9-124.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 86 | 69.8 | 123.1 | (98.5-152.1) |  | Male | 478 | 505.9 | 94.5 | (86.2-103.3) |
| Female | 76 | 72.7 | 104.6 | (82.4-130.9) |  | Female | 534 | 514.3 | 103.8 | (95.2-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

107

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 10 | 10.9 | 92.1 | (44.1-169.5) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 8 | 12.6 | 63.5 | (27.3-125.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

108

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 21.3 | 75.1 | (42.9-121.9) |  | Male | 24 | 13.2 | 182.3 | (116.7-271.2) |
| Female | 1 | 7.2 | nc | (nc-nc) |  | Female | 11 | 9.9 | 111.1 | (55.4-198.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 3.7 | 216.7 | (93.3-427.0) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 11 | 11.7 | 93.9 | (46.8-168.0) |
| Female | 98 | 80.1 | 122.3 | (99.3-149.1) |  | Female | 7 | 9.8 | 71.2 | (28.5-146.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 9.4 | 85.4 | (36.8-168.4) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 2 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 22.0 | 91.1 | (55.6-140.7) |  |  |  |  |  |  |
| Female | 20 | 20.4 | 98.0 | (59.8-151.4) |  | Female | 6 | 6.9 | 87.1 | (31.8-189.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.1 | 116.9 | (42.7-254.4) |  | Male | 4 | 7.7 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 6 | 7.5 | 80.3 | (29.3-174.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 1.4 | 364.5 | (117.5-850.5) |  | Male | 63 | 58.3 | 108.1 | (83.0-138.2) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 11.4 | 166.7 | (100.3-260.3) |  | Male | 8 | 4.9 | 163.8 | (70.5-322.8) |
| Female | 8 | 6.4 | 124.6 | (53.7-245.6) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 8.3 | 121.2 | (58.0-222.9) |  | Male | 7 | 5.0 | 139.2 | (55.8-286.8) |
| Female | 6 | 5.8 | 103.6 | (37.8-225.6) |  | Female | 20 | 14.5 | 137.5 | (84.0-212.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 18 | 18.2 | 98.8 | (58.5-156.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 35.6 | 95.6 | (66.2-133.5) |  | Male | 274 | 257.9 | 106.3 | (94.1-119.6) |
| Female | 42 | 37.8 | 111.2 | (80.1-150.3) |  | Female | 278 | 268.2 | 103.6 | (91.8-116.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

109

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 65 | 67.5 | 96.2 | (74.3-122.7) |  | Male | 48 | 44.0 | 109.1 | (80.4-144.6) |
| Female | 26 | 26.1 | 99.8 | (65.2-146.2) |  | Female | 29 | 36.9 | 78.5 | (52.6-112.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 13.5 | 59.2 | (25.5-116.6) |  | Male | 12 | 13.9 | 86.4 | (44.6-151.0) |
| Female | 8 | 12.3 | 65.1 | (28.0-128.3) |  | Female | 6 | 12.1 | 49.5 | (18.1-107.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 40 | 39.1 | 102.3 | (73.1-139.3) |
| Female | 280 | 287.4 | 97.4 | (86.4-109.5) |  | Female | 28 | 35.8 | 78.2 | (51.9-113.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 31 | 32.4 | 95.7 | (65.0-135.8) |
| Female | 22 | 9.8 | 223.5 | (140.0-338.3) |  | Female | 10 | 15.8 | 63.1 | (30.2-116.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 61 | 71.3 | 85.5 | (65.4-109.8) |  |  |  |  |  |  |
| Female | 82 | 75.8 | 108.2 | (86.0-134.3) |  | Female | 26 | 25.1 | 103.7 | (67.7-152.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 17.0 | 58.8 | (28.1-108.1) |  | Male | 30 | 25.1 | 119.6 | (80.7-170.8) |
| Female | 4 | 5.0 | nc | (nc-nc) |  | Female | 30 | 27.4 | 109.4 | (73.8-156.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  | Male | 194 | 201.5 | 96.3 | (83.2-110.8) |
| Female | 8 | 5.1 | 156.1 | (67.2-307.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 55 | 39.4 | 139.5 | (105.1-181.6) |  | Male | 22 | 15.9 | 138.2 | (86.6-209.3) |
| Female | 20 | 23.1 | 86.4 | (52.8-133.5) |  | Female | 6 | 10.7 | 56.2 | (20.5-122.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 9.9 | nc | (nc-nc) |  | Male | 9 | 11.2 | 80.4 | (36.7-152.6) |
| Female | 4 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 28.1 | 71.2 | (43.5-110.0) |  | Male | 22 | 18.6 | 118.4 | (74.2-179.2) |
| Female | 19 | 22.0 | 86.5 | (52.0-135.0) |  | Female | 70 | 56.3 | 124.4 | (97.0-157.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 29 | 24.0 | 121.0 | (81.0-173.8) |  |  |  |  |  |  |
| Female | 8 | 8.7 | 92.1 | (39.7-181.5) |  | Female | 63 | 64.1 | 98.2 | (75.5-125.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 101 | 117.3 | 86.1 | (70.1-104.6) |  | Male | 816 | 867.7 | 94.0 | (87.7-100.7) |
| Female | 124 | 133.6 | 92.8 | (77.2-110.7) |  | Female | 955 | 976.6 | 97.8 | (91.7-104.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

110

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 29.5 | 94.8 | (63.0-137.1) |  | Male | 22 | 20.0 | 109.8 | (68.8-166.2) |
| Female | 9 | 10.8 | 83.6 | (38.2-158.7) |  | Female | 19 | 16.6 | 114.1 | (68.7-178.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.3 | 79.9 | (25.8-186.5) |  | Male | 10 | 6.3 | 157.8 | (75.5-290.2) |
| Female | 5 | 5.5 | 90.9 | (29.3-212.2) |  | Female | 6 | 5.1 | 117.7 | (43.0-256.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 19 | 17.7 | 107.0 | (64.4-167.2) |
| Female | 148 | 135.3 | 109.4 | (92.5-128.5) |  | Female | 15 | 15.5 | 96.7 | (54.1-159.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 15.5 | 115.9 | (68.7-183.2) |
| Female | 8 | 4.9 | 164.3 | (70.8-323.8) |  | Female | 4 | 7.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 30 | 32.7 | 91.7 | (61.8-130.8) |  |  |  |  |  |  |
| Female | 23 | 32.4 | 71.1 | (45.0-106.6) |  | Female | 15 | 11.3 | 132.4 | (74.0-218.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.8 | 102.7 | (44.2-202.4) |  | Male | 15 | 11.3 | 132.9 | (74.3-219.2) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 7 | 11.2 | 62.6 | (25.1-129.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 96 | 93.9 | 102.3 | (82.8-124.9) |
| Female | 4 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 18.8 | 79.8 | (44.6-131.7) |  | Male | 12 | 7.2 | 167.1 | (86.2-291.8) |
| Female | 18 | 10.4 | 173.3 | (102.7-274.0) |  | Female | 5 | 4.6 | 109.8 | (35.4-256.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.6 | 153.8 | (61.6-316.8) |  | Male | 11 | 4.7 | 234.8 | (117.0-420.1) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 12.7 | 118.3 | (66.2-195.2) |  | Male | 16 | 9.0 | 178.7 | (102.1-290.2) |
| Female | 4 | 9.3 | nc | (nc-nc) |  | Female | 40 | 27.6 | 145.2 | (103.7-197.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 11.1 | 53.9 | (19.7-117.3) |  |  |  |  |  |  |
| Female | 0 | 3.7 | nc | (nc-nc) |  | Female | 43 | 29.4 | 146.4 | (105.9-197.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 52.6 | 72.3 | (51.1-99.2) |  | Male | 407 | 396.1 | 102.8 | (93.0-113.2) |
| Female | 38 | 56.8 | 66.9 | (47.3-91.8) |  | Female | 436 | 436.4 | 99.9 | (90.7-109.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

111